• 1. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 2. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 3. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

Research Briefing on 1,3-Dioxolane, 2-(3-bromo-4-methylphenyl)- (CAS: 124717-60-8) in Chemical Biology and Pharmaceutical Applications

1,3-Dioxolane, 2-(3-bromo-4-methylphenyl)- (CAS: 124717-60-8) is a specialized chemical compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This briefing synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and therapeutic potential. The compound's unique structural features, including the dioxolane ring and bromo-methylphenyl moiety, make it a promising candidate for drug discovery and development.

Recent studies have explored the synthetic pathways for 1,3-Dioxolane, 2-(3-bromo-4-methylphenyl)-, with a focus on optimizing yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel catalytic method that achieves a 92% yield under mild conditions, significantly improving upon previous methods. This advancement is critical for scaling up production for preclinical and clinical studies. Additionally, the compound's stability under physiological conditions has been investigated, with findings suggesting it is sufficiently stable for in vivo applications.

In terms of biological activity, 1,3-Dioxolane, 2-(3-bromo-4-methylphenyl)- has shown promising results in preliminary screenings against various cancer cell lines. A study published in Bioorganic & Medicinal Chemistry Letters (2024) reported that the compound exhibits selective cytotoxicity against breast cancer cells (MCF-7) with an IC50 value of 3.2 μM, while showing minimal toxicity toward normal cells. Mechanistic studies suggest that the compound induces apoptosis via the mitochondrial pathway, highlighting its potential as a targeted anticancer agent.

Further research has explored the compound's potential in neurodegenerative diseases. A 2023 study in ACS Chemical Neuroscience demonstrated that 1,3-Dioxolane, 2-(3-bromo-4-methylphenyl)- could modulate alpha-synuclein aggregation, a key pathological feature of Parkinson's disease. The compound reduced fibril formation by 40% in vitro, suggesting its utility as a scaffold for developing neuroprotective agents. These findings open new avenues for therapeutic intervention in neurodegenerative disorders.

Despite these promising results, challenges remain in the development of 1,3-Dioxolane, 2-(3-bromo-4-methylphenyl)- as a therapeutic agent. Pharmacokinetic studies indicate that the compound has moderate bioavailability, necessitating further structural modifications to enhance its drug-like properties. Additionally, comprehensive toxicity studies are required to ensure its safety profile. Ongoing research aims to address these limitations through medicinal chemistry optimization and advanced formulation strategies.

In conclusion, 1,3-Dioxolane, 2-(3-bromo-4-methylphenyl)- (CAS: 124717-60-8) represents a versatile compound with significant potential in chemical biology and pharmaceutical applications. Its unique structural attributes and demonstrated biological activities make it a valuable candidate for further investigation. Future research should focus on optimizing its pharmacokinetic properties and expanding its therapeutic applications, paving the way for its translation into clinical use.

• 35822-58-3(1-Bromo-2-(diethoxymethyl)benzene)
• 773094-77-2(1,3-Dioxolane, 2-(3,5-dibromophenyl)-)
• 139194-78-8(1,3-Dioxolane, 2-(2,5-dibromophenyl)-)
• 34824-58-3(2-(2-Bromophenyl)-1,3-dioxolane)
• 861928-15-6(Benzene, 1,4-dibromo-2-(dimethoxymethyl)-)
• 91587-27-8(2-(4-bromo-2-methylphenyl)-1,3-dioxolane)
• 88679-81-6(1,3-Dioxolane, 2-(4-bromo-2,6-dimethylphenyl)-)
• 655237-91-5(3-BROMO-4-METHYLBENZALDEHYDE DIMETHYL ACETAL)
• 17789-14-9(2-(3-Bromophenyl)-1,3-dioxolane)
• 10602-01-4(2-(4-Bromophenyl)-1,3-dioxolane)